Unusual Dyslipidemia in Patients with  Chronic Kidney Diseases

Phukan, Rashmi Rekha; Goswami, Rohini Kanta

doi:10.7860/jcdr/2017/24172.9220

Cited by 9 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the lipid profile, the results obtained were compatible with a recent study which concluded that an elevation of triglycerides with a reduction in HDL-C, instead of an increase in total cholesterol and LDL, are responsible for the high incidence of cardiovascular complications in patients with CKD [32]. In addition, there was a significant correlation between total cholesterol and MPO parame-▶table 2 Biochemical and hematological parameters of the groups: control (CON), end-stage renal disease (ESRD) and end-stage renal disease with cardiovascular disease (ESRD/CVD).…”

Section: Discussionsupporting

confidence: 89%

Serum Myeloperoxidase, C-reactive Protein and α1-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease

Rickli

Borato

Silva

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Background Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD). Elevated serum concentrations of myeloperoxidase (MPO) are associated with an increased risk of developing CVD. The objective of this study was to evaluate serum MPO levels, as well as other laboratory parameters, in individuals with ESRD, with and without CVD, undergoing hemodialysis. Methods 80 volunteers were admitted, divided into the following groups: control group (CON): 20 individuals without chronic kidney disease (CKD); ESRD group: 45 individuals with CKD stage V and ESRD/CVD group: 15 individuals with CKD stage V and with CVD. The following biomarkers were evaluated: MPO, High sensitivity C-reactive protein (hs-CRP) and α1-acid glycoprotein, following the manufacturer's guidelines in the package inserts. The data were processed through the statistical software SPSS 20.0®. Results The level of MPO for the CON group was 84 ng/mL (73–87 ng/mL), for the ESRD group 77 ng/mL (11–89 ng/mL) and for the ESRD/CVD group 21 ng/mL (8–47 ng/mL), with a significant statistical difference of the ESRD/CVD group from the CON and ESRD groups (p<0.001). For the parameters hs-CRP and α1-acid glycoprotein a statistical difference between the ESRD and ESRD/CVD groups from the CON group (p<0.0001) was observed, but not between the ESRD and ESRD/CVD groups. Conclusion It is suggested that further studies should be performed to define the potential role of MPO as a cardiovascular risk marker for patients with ESRD on hemodialysis.

show abstract

Section: Discussionsupporting

confidence: 89%

Serum Myeloperoxidase, C-reactive Protein and α1-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease

Rickli

Borato

Silva

et al. 2019

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…These observations are similar to study from north India which revealed that increased TG, increased VLDL-C and reduced HDL-C levels rather than increased TC and LDL-C levels are responsible for increased cardiovascular complications in CKD patients. 32 Ahmad et al in a study in 2018 observed increased TC,TG, LDL-C and VLDL-C and reduced HDL-C levels in CKD patients with and without hemodialysis as high risk for development of dyslipidemia as hemodialysis effectively reduces the nitrogenous waste products but fails to clear dyslipidemia. 33 In hemodialysis there is more oxidative stress leading to dyslipidemia.…”

Section: Discussionmentioning

confidence: 99%

Study of lipid profile in diabetic and non-diabetic chronic kidney disease patients on haemodialysis: a prospective comparative study from a sub Himalayan region in North India

Nand

Kumar

2020

Int J Adv Med

View full text Add to dashboard Cite

Background: Diabetes mellitus (DM) is a major cause of chronic kidney disease (CKD) leading to diabetic kidney disease (DKD). Several studies have observed lipid profile abnormalities in non-diabetic CKD patients with and without haemodialysis. Our study aims to reveal lipid profile abnormalities both in DKD and non-diabetic CKD patients on haemodialysis.Methods: A prospective comparative study included 50 DKD and 50 non-diabetic CKD patients on haemodialysis and 50 controls after fulfilling the inclusion and exclusion criteria. The demographic and biochemical, including lipid profile parameters data of all subjects was collected and statistically analysed. p<0.05 was considered as statically significant.Results: A total of 100 study patients, 50 DKD and 50 non-diabetic CKD patients, both on haemodialysis revealed significant dyslipidaemia when compared to controls. Total cholesterol in DKD patients on haemodialysis when compared to controls (177.5±80.5 versus 146.5±31.8 mg/dl) was significantly elevated (p=0.01). Low density lipoprotein (LDL) in DKD patients when compared to controls (94.1±43.3 versus 76.3±26.3 mg/dl) was also significantly elevated (p=0.01). Triglyceride levels in both DKD and non-diabetic CKD patients on haemodialysis in comparison to controls (213.8±182.1 and 169.2±132.3 versus 109.2±28.9 mg/dl respectively) were significantly elevated (p=0.0002 and p=0.003 respectively). Similarly, very low-density lipoprotein (VLDL) levels in both DKD and non-diabetic CKD patients were also significantly elevated when compared to controls (p=0.002 and p=0.003 respectively) whereas high density lipoprotein (HDL) was significantly reduced.Conclusion: Both DKD and non-diabetic CKD patients on haemodialysis revealed significant dyslipidaemia, a major cause of increased risk for cardiovascular diseases necessitating early treatment with statins.

show abstract

“…Patients with CKD show alterations in the serum lipid profile which differ from those in the general population. A recent study showed that, although the total cholesterol was low in patients with CKD, the triglyceride elevation, VLDL and HDL cholesterol decrease were responsible for cardiovascular events 10 .…”

Section: Lipid Intakementioning

confidence: 99%

Nutritional patterns in chronic kidney disease

Mihalache¹,

Gârneaţă²,

Mircescu³

2018

Arch Balk Med Union

View full text Add to dashboard Cite

Modèles nutritionnels dans la maladie rénale chronique La maladie rénale chronique est un problème de santé publique lié non seulement à la difficulté du traitement de remplacement rénal, mais également au risque cardiovasculaire accru et à la mortalité plus élevée. Des données émergentes suggèrent que les habitudes alimentaires jouent un rôle plus important que les aliments dans la maladie rénale chroniques. Ainsi, plusieurs macro produits nutritionnels, en particulier un apport élevé en protéines, pourraient constituer des facteurs de risque d'IRC, alors qu'un régime végétarien, méditerranéen ou DASH pourrait être au moins aussi efficace qu'une restriction protéique pour réduire la progression de l'IRC. Cette revue résume l'association entre plusieurs macro-/ micro produits nutritionnels et l'IRC, ainsi que les données existantes sur la relation entre les habitudes alimentaires et l'évolution de la maladie rénale Mots-clés: nutrition, maladie rénale chronique, régimes alimentaires.

show abstract

Unusual Dyslipidemia in Patients with Chronic Kidney Diseases

Cited by 9 publications

References 17 publications

Serum Myeloperoxidase, C-reactive Protein and α1-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease

Serum Myeloperoxidase, C-reactive Protein and α1-acid Glycoprotein: Insights about Cardiovascular Risk in End-stage Renal Disease

Study of lipid profile in diabetic and non-diabetic chronic kidney disease patients on haemodialysis: a prospective comparative study from a sub Himalayan region in North India

Nutritional patterns in chronic kidney disease

Contact Info

Product

Resources

About